# TTI-101 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tti-101

> The next catalyst for TTI-101, sponsored by Tvardi Therapeutics, Inc. (TVRD), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for TTI-101?

The next catalyst for TTI-101, sponsored by Tvardi Therapeutics, Inc. (TVRD), is its topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation." [Calendar and source filings](https://sec-api.dev/pdufa/tti-101)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126507, https://www.sec.gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/pdufa/tti-101#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | TTI-101 |
| Codes | TTI-101 |
| Sponsor | Tvardi Therapeutics, Inc. (TVRD) https://sec-api.dev/companies/tvrd/catalysts |
| Indications | [idiopathic pulmonary fibrosis](https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis), suffering, hcc early |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Aug 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: suffering.
- First seen 2025-05-30, last confirmed 2025-05-30.
- SEC registration statement (S-1) (accession 0001104659-25-054853): "In August 2023, we dosed the first patient in our ongoing 12-week REVERT IPF Phase 2 clinical trial for the treatment of patients suffering from IPF." https://www.sec.gov/Archives/edgar/data/1346830/000110465925054853/tvrd-20250331xs1.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2024-12-18, last confirmed 2025-04-01.
- Press release filed with the SEC (EX-99) (accession 0001104659-24-129596): "Preliminary topline data from the REVERTLIVER CANCER study is anticipated in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1346830/000110465924129596/tm2431150d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-030583): "Tvardi expects to report unblinded data from its Phase 2 IPF clinical trial in the second half of 2025 and anticipate preliminary topline data from its HCC Phase 1b/2 HCC clinical trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1346830/000110465925030583/tm2510381d1_ex99-2.htm

### August 14, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Idiopathic Pulmonary Fibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05671835 (Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Tvardi Therapeutics, Incorporated." https://clinicaltrials.gov/study/NCT05671835

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: idiopathic pulmonary fibrosis.
- First seen 2024-12-18, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-078665): "2 trial of TTI-101, for patients with idiopathic pulmonary fibrosis (IPF); topline data on track for Q4 2025." https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-052733): "Topline data from the REVERTIPF trial anticipated in 4Q 2025" https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/tm2516173d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-052733): "Topline data is expected in Q4 of this year."" https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/tm2516173d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-035121): "Tvardi anticipates reporting topline data from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis (IPF), in the second half of 2025, followed by its program in hepatocellular carcinoma (HCC) in the first half of 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465925035121/tm2512159d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-129596): "Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma" https://www.sec.gov/Archives/edgar/data/1346830/000110465924129596/tm2431150d1_ex99-1.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2025-04-15, last confirmed 2025-11-13.
- SEC Form 8-K (accession 0001104659-25-035121): "We plan to report preliminary topline data from this clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925035121/tm2512159d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111310): "Preliminary topline data from the company's ongoing REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 anticipated in the first half of 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-047856): "Preliminary topline data from the company's ongoing REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 anticipated in 1H 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-035121): "IPF clinical trial in the second half of 2025 and anticipate preliminary topline data from its HCC Phase 1b/2 clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925035121/tm2512159d1_8k.htm
- SEC Form 10-Q (accession 0001104659-25-111289): "Tvardi expects to report preliminary topline data from its Phase 1b/2 HCC clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925111289/tvrd-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011562): "Tvardi expects to report unblinded data from its Phase 2 IPF clinical trial in the fourth quarter of 2025 and anticipate preliminary topline data from its Phase 1b/2 HCC clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000155837025011562/tvrd-20250630x10q.htm
- SEC registration statement (S-1) (accession 0001104659-25-054853): "We expect to report unblinded data from our Phase 2 IPF clinical trial in the fourth quarter of 2025 and anticipate preliminary topline data from its Phase 1b/2 HCC clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925054853/tvrd-20250331xs1.htm
- SEC registration statement (S-1) (accession 0001104659-25-054853): "We expect to report unblinded data from our Phase 2 IPF clinical trial in the fourth quarter of 2025 and anticipate preliminary topline data from our Phase 1b/2 HCC clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925054853/tvrd-20250331xs1.htm
- SEC Form 10-Q (accession 0001558370-25-007575): "Tvardi expects to report unblinded data from its Phase 2 IPF clinical trial in the second half of 2025 and anticipates preliminary topline data from its Phase 1b/2 HCC clinical trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000155837025007575/tvrd-20250331x10q.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-08-14, last confirmed 2025-11-13.
- SEC Form 10-Q (accession 0001104659-25-111289): "A Phase 1 trial of TTI-109 in healthy volunteers to evaluate safety, tolerability, and pharmacokinetics, as well as bioequivalence to TTI-101, is ongoing and Tvardi expects to report out topline data from this trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925111289/tvrd-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111310): "On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111310): "Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-078665): "Liver Cancer trial continues to enroll patients, and we remain on track to report topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_ex99-1.htm

### 2H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2026-03-31, last confirmed 2026-03-31.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-037724): "Preliminary topline data from the company's ongoing REVERT LIVER CANCER Phase 1b/2 clinical trial of TTI-101, anticipated in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1/2.
- First seen 2026-03-31, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057524): "TTI-101 (HCC - REVERT LIVER CANCER study): Phase 1b/2 trial remains on track to report topline results in 2H 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-096424): "We expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 clinical trial in patients with HCC in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1346830/000110465926096424/tvrd-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-057528): "Subsequently, in the second half of 2026, we expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 clinical trial." https://www.sec.gov/Archives/edgar/data/1346830/000110465926057528/tvrd-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-037729): "Subsequently, in the second half of 2026, we expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 clinical trial." https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-037729): "We plan to report topline data from the REVERT LIVER CANCER trial in the second half of 2026 and use those data to inform our pivotal development strategy." https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057524): "Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-037724): "Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026" https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1/2. Indication: HCC early.
- First seen 2026-11-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126507): "The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation." https://www.sec.gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-126508): "We expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 clinical trial in patients with HCC early in the first quarter of 2027 to allow for complete cohort evaluation." https://www.sec.gov/Archives/edgar/data/1346830/000110465926126508/tvrd-20260930x10q.htm

## Same indication

- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [LTI-03](https://sec-api.dev/pdufa/lti-03) (RNTX)
- [LTSE-2578](https://sec-api.dev/pdufa/ltse-2578) (GPCR)
- [Ofev® (nintedanib)](https://sec-api.dev/pdufa/nintedanib) (AVLN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tti-101.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TTI-101 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tti-101

```bibtex
@misc{secapidev_pdufa_tti_101_20261116,
  title        = {TTI-101 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tti-101}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tti_101_20261116","title":"TTI-101 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tti-101","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
